Jefferies Lowers its EPS Estimates on ARIAD Pharmaceuticals (ARIA), Maintains Buy Rating and Price Target
Tweet Send to a Friend
Jefferies keeps the Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) and at a price target of $6. The firm did ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
